AmSurg (Nasdaq: AMSG) reported earnings on April 23. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), AmSurg met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded. Non-GAAP earnings per share grew. GAAP earnings per share expanded significantly.

Gross margins grew, operating margins dropped, net margins increased.

Revenue details
 AmSurg logged revenue of $260.1 million. The seven analysts polled by S&P Capital IQ hoped for a top line of $261.4 million on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $230.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.52. The eight earnings estimates compiled by S&P Capital IQ predicted $0.52 per share. Non-GAAP EPS of $0.52 for Q1 were 4.0% higher than the prior-year quarter's $0.50 per share. (The prior-year quarter included -$0.03 per share in earnings from discontinued operations.) GAAP EPS of $0.56 for Q1 were 19% higher than the prior-year quarter's $0.47 per share. (The prior-year quarter included -$0.03 per share in earnings from discontinued operations.)

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 85.5%, much better than the prior-year quarter. Operating margin was 30.6%, 20 basis points worse than the prior-year quarter. Net margin was 6.8%, 40 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $266.1 million. On the bottom line, the average EPS estimate is $0.55.

Next year's average estimate for revenue is $1.07 billion. The average EPS estimate is $2.18.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 141 members out of 149 rating the stock outperform, and eight members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give AmSurg a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AmSurg is hold, with an average price target of $29.50.

Is AmSurg the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.